Key points are not available for this paper at this time.
Abstract Background JAK inhibitors are well known for the treatment of rheumatoid arthritis (RA), but whether they can be used to treat pulmonary fibrosis, a common extra‐articular disease of RA, remains to be clarified. Methods A jak2 inhibitor, CEP33779 (CEP), was administered to a rat model of RA‐associated interstitial lung disease to observe the degree of improvement in both joint swelling and pulmonary fibrosis. HFL1 cells were stimulated with TGF‐β1 to observe the expression of p‐JAK2. Then, different concentrations of related gene inhibitors (JAK2, TGFβ‐R1/2, and p‐STAT3) or silencers (STAT3, JAK2) were administered to HFL1 cells, and the expression levels of related proteins were detected to explore the underlying mechanisms of action. Results CEP not only reduced the degree of joint swelling and inflammation in rats but also improved lung function, inhibited the pro‐inflammatory factors IL‐1β and IL‐6, reduced lung inflammation and collagen deposition, and alleviated lung fibrosis. CEP decreased the expression levels of TGFβ‐R2, p‐SMAD, p‐STAT3, and ECM proteins in rat lung tissues. TGF‐β1 induced HFL1 cells to highly express p‐JAK2, with the most pronounced expression at 48 h. The levels of p‐STAT3, p‐SMAD3, and ECM‐related proteins were significantly reduced after inhibition of either JAK2 or STAT3. Conclusion JAK2 inhibitors may be an important and novel immunotherapeutic drug that can improve RA symptoms while also delaying or blocking the development of associated pulmonary fibrotic disease. The mechanism may be related to the downregulation of p‐STAT3 protein via inhibition of the JAK2/STAT signaling pathway, which affects the phosphorylation of SMAD3.
Wei et al. (Wed,) studied this question.